1/ #IMS25 🧵 I don’t live-tweet often, but this presentation will be worth it!
@myelomaMD discussing upcoming #MMsm myeloma response criteria.
Part 1: setting stage for why an update is needed…
2/ #IMS25
Now a discussion of where we’ve come, and what the status quo is for defining measurable disease for trials. @myelomaMD #MMsm
@myelomaMD 3/ #IMS25
🚨 MR is going away as a level of non-response.
24-hour urine really no longer required unless confirming CR or only measurable dz 👏
sCR is disappearing as well! This is excellent since it was always confusing.
@myelomaMD 4/ #IMS25 moving to imaging…
New technologies & grading have been embraced - Deauville staging for myeloma #MMsm as part of confirming CR if using PET.
dwMRI will also suffice as well. This makes much more sense!
@myelomaMD 5/ #IMS25 moving to MRD - lots of fascinating points.
Unfortunately MRD-neg CR still must be reported to maintain historical consistency, even though MRD-neg ≥VGPR is probably what matters.
New “stringent MRD” criteria in the works… will be first step toward defining cure!
@myelomaMD 6/ #IMS25 moving to a few other points before modifications to PD.
For IgA #MMsm, use quant IgA levels and not SPEP…
And now changes to PD next!
@myelomaMD 7/ #IMS25 many changes to PD:
1️⃣ if 2 markers meet PD criteria at once, no need for confirmation
2️⃣ LC escape now recognized - PD by any marker counts.
@myelomaMD 8/ #IMS25 summary slide by @myelomaMD
Summarizing many great points including waving bye👋 sCR and MR…
For MRD, he emphasizes that intent-to-treat analyses imperative (all patients, not just those who had a marrow done to assess for it!)
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.